

CURRICULUM VITAE

October 2012

AZHER ARAFAH, Pharm.D., Ph.D.
King Saud University

PERSONAL DATA

Office Address: College of Pharmacy
Clinical Pharmacy Department
King saud University
P.O. Box 2457
Riyadh 11451, Saudi Arabia
Office A1 223
Phone: +96614677485

Email: Email: aazher@ksu.edu.sa

Professional Licensure: Minnesota Board of Pharmacy, 2008-present (active)
Riyadh, Saudi Arabia, Board of Pharmacy 2002-present (active)

EDUCATION AND TRAINING

2007-2012 **DOCTOR OF PHILOSOPHY,**
Major; Experimental and Clinical Pharmacology, Minor; Human Genetics
University of Minnesota, Minneapolis, Minnesota

2004-2007 **DOCTOR OF PHARMACY,**
North Dakota State University, Fargo, North Dakota

1996-2002 **BACHELOR OF SCIENCE IN PHARMACY,**
King Saud University, Riyadh, Saudi Arabia

PROFESSIONAL EXPERIENCE

10/2012-present **ASSISTANT PROFESSOR**
Clinical Pharmacy Department
College of Pharmacy, King Saud University
Riyadh, Saudi Arabia

12/2002-06/2004 **TEACHING ASSISTANT**
Clinical Pharmacy Department
College of Pharmacy, King Saud University
Riyadh, Saudi Arabia

01/2002-12/2002 **PHARMACIST**
King Faisal Specialist Hospital & Research Center
Riyadh, Saudi Arabia

AWARDS AND HONORS

02/2006 Dean's honor list, North Dakota State University
08/2005 Dean's honor list, North Dakota State University

PROFESSIONAL MEMBERSHIPS

2012-present American Heart Association (AHA)
2007-Present American Society for Clinical Pharmacology and Therapeutics (ASCPT)

ABSTRACTS AND POSTER PRESENTATIONS

1. **Arafah A**, Guillemette C, Tsai M, Boreen C, Straka R. Evidence of *UGT2B7* as a pharmacogenetic determinant of variability in serum fenofibric acid levels in human subjects. Arteriosclerosis, Thrombosis and Vascular Biology 2012 scientific sessions. April 18-20, 2012
2. **Arafah A**, Oetting W, Tsai M, Straka R. Fenofibrate and the Pharmacogenetic Impact (FPI): The influence of select UGT genetic variants on the pharmacokinetic profile of fenofibrate in healthy subjects. Presented at the Rho Chi Research Symposium, University of Minnesota, Minneapolis, Minnesota, March 22, 2011
3. Boreen C, **Arafah A**, Oetting W, Tsai M, Straka R. The pharmacogenetic impact of apolipoprotein E on lipid-altering response to fenofibrate. Presented at the Rho Chi Research Symposium, University of Minnesota, Minneapolis, Minnesota, March 22, 2011
4. Straka RJ, Krishnan P, Li N, **Arafah A**, Ordovas JM, Arnett DK, Guillemette C. The Effect of *UGT1A1* TA Repeat Variant on Fenofibric Acid Concentration and Triglyceride Response Clinical Pharmacology and Therapeutics, 2009;85(1) PI-09 S10, Presented at the Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics, Washington, DC, March 19, 2009
5. **Arafah A**, Peterson J, Li N, Arnett DK, Straka RJ. The Pharmacogenetics of Renal Transporters (OAT1, OAT2 and OCT2) on Triglyceride Response to Fenofibrate *in vivo* Considering Co-administered Drugs Abstract Presentation (Poster) at Pharmacogenomics Meeting Cold Spring Harbor Laboratory, Cold Spring Harbor, NY November 20, 2008
6. Straka, RJ, Li N, Tsai AK, **Arafah A**, Ordovas JM, Guillemette C, Arnett DK. Pharmacogenetics and the Role of *UGT2B7* in the Disposition and Triglyceride Response to Fenofibrate. Circulation 2008;118:S_326 Oral (Podium) Presentation at the American Heart Association Scientific Sessions Orlando, Florida, November 10, 2008

MANUSCRIPT IN PROGRESS

1. **Arafah A**, Guillemette C, Oetting W, Tsai M, Straka R. Fenofibrate and the Pharmacogenetic Impact (FPI): Fenofibrate and the Pharmacogenetic Impact (FPI): The *in vivo* role of *UGT2B7* as a determinant of serum fenofibric acid levels in healthy subjects. Expected publication date 2012
2. **Arafah A**, An P, Krishnan P, Ordovas J, Tsai M, Arnett D, Straka R. Comparing the effect of fenofibrate on serum bilirubin levels between *UGT1A1**28 genotypes. Expected publication date 2012

3. **Arafah A**, An P, Krishnan P, Ordovas J, Tsai M, Arnett D, Straka R. Using genetic variation for the prediction of uric acid levels from GOLDN study. Expected publication date 2012

PRESENTATIONS

- | | |
|---------|---|
| 04/2012 | Evidence of <i>UGT2B7</i> as a pharmacogenetic determinant of variability in serum fenofibric acid levels in human subjects. American Heart Association scientific sessions “Arteriosclerosis, Thrombosis and Vascular Biology 2012”. Chicago, Illinois |
| 09/2010 | Implementing Pharmacogenetics to Optimize the Use of Fenofibrate in Controlling Cardiovascular Residual Risk. Experimental and Clinical Pharmacology Department, Seminar presentation, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota |
| 10/2009 | Genetic determinants of Fenofibrate Response: What we have learned so far. Experimental and Clinical Pharmacology Department, Seminar presentation, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota |
| 08/2008 | Studies of the Pharmacogenetics impact of UGTs on Fenofibrate response. Experimental and Clinical Pharmacology Department, Seminar presentation, University of Minnesota, College of Pharmacy, Minneapolis, Minnesota |
| 04/2006 | Gout, Pharmacotherapy class: Rheumatology/Endocrinology, North Dakota State University, College of Pharmacy, Fargo, North Dakota |
| 02/2006 | Meningitis, MeritCare hospital, Fargo, North Dakota |
| 07/2002 | Generalized Anxiety Disorder, King Faisal Specialist Hospital & Research Center, 2002. Riyadh, Saudi Arabia |
| 05/2002 | Acute Myocardial Infarction, King Faisal Specialist Hospital & Research Center, 2002. Riyadh, Saudi Arabia |

SYMPOSIUMS AND WORKSHOPS

- | | |
|---------------|---|
| 04/18-20/2012 | American Heart Association scientific sessions “Arteriosclerosis, Thrombosis and Vascular Biology 2012”. Chicago, Illinois |
| 11/19-22/2008 | Pharmacogenomics meeting. Cold Spring Harbor Laboratories, Cold Spring Harbor, New York. |
| 04/20/2007 | North Dakota Pharmacists Association Convention 2007: Day 1. Fargo, North Dakota |
| 10/6-9/2003 | 6 th International Saudi Pharmacy Conference. Pharmacy profession towards patient care. Saudi Pharmaceutical Society, Riyadh, Saudi Arabia |
| 10/15-17/2002 | 3 rd KFMMC International Pharmacy Conference “Future Trend” Dhahran, Saudi Arabia |

09/19/2002	1 st Symposium of Psychiatric Pharmacy. Riyadh, Saudi Arabia
04/06/2002	Workshop on “fundamentals of conducting research” in King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
02/12/2002	Completed the course of Education and Training in IV Admixture: Infection Control, Aseptic Technique and Potassium Guidelines. King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
04/04/2001	Basic Principles of Adult TPN Workshop, Riyadh, Saudi Arabia

EXTRACURRICULAR ACTIVITIES

12/2006	Glucose, cholesterol and blood pressure screening and medication consultation in a homeless shelter, Fargo, North Dakota
06/2006	Glucose, cholesterol and blood pressure screening for the public. In the “Big Iron” event.. Fargo, North Dakota
05/2002	Member in the first Medication Awareness Day in King Faisal Specialist Hospital & Research Center. Riyadh, Saudi Arabia
04/2002	Participation in the Saudi Career and Development Program (SCDP) Day, Riyadh, Saudi Arabia
06/2002	Member in the patient education committee in King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia
10/2000	Member of the scientific committee in the 1 st Annual Exhibition for Pharmaceutical Education, collage pharmacy, King Saud University. Riyadh, Saudi Arabia